Martin ZapataLaguado· @zapatalaguadomd · X·· 1 天前评分70
正文 · 原文
#ESMO26 | VOLGA in cisplatin-ineligible MIBC: Durvalumab + enfortumab vedotin significantly improved: OS: HR 0.58 (p=0.0027) EFS: HR 0.51 (p<0.0001) 2-year OS: 78% vs 69%ctDNA clearance: 60%
A major advance in MIBC@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily
41 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Martin ZapataLaguado · x.com